Focused Ultrasound-mediated Enhancement of Blood-brain Barrier Permeability for Brain Tumor Treatment: a Systematic Review of Clinical Trials

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Aug 29

PMID 39207625

Authors

Honglin Zhu

Caitlin Allwin

Monica G Bassous

Antonios N Pouliopoulos

Affiliations

Soon will be listed here.

Abstract

Purpose: Brain tumors, particularly glioblastoma multiforme (GBM), present significant prognostic challenges despite multimodal therapies, including surgical resection, chemotherapy, and radiotherapy. One major obstacle is the limited drug delivery across the blood-brain barrier (BBB). Focused ultrasound (FUS) combined with systemically administered microbubbles has emerged as a non-invasive, targeted, and reversible approach to transiently open the BBB, thus enhancing drug delivery. This review examines clinical trials employing BBB opening techniques to optimise pharmacotherapy for brain tumors, evaluates current challenges, and proposes directions for further research.

Methods: A systematic literature search was conducted in PubMed and ClinicalTrials.gov up to November 2023, searching for "ultrasound" AND "brain tumor". The search yielded 1446 results. After screening by title and abstract, followed by full-text screening (n = 48), 35 studies were included in the analysis.

Results: Our analysis includes data from 11 published studies and 24 ongoing trials. The predominant focus of these studies is on glioma, including GMB and astrocytoma. One paper investigated brain metastasis from breast cancer. Evidence indicates that FUS facilitates BBB opening and enhances drug uptake following sonication. Exploration of FUS in the pediatric population is limited, with no published studies and only three ongoing trials dedicated to this demographic.

Conclusion: FUS is a promising strategy to safely disrupt the BBB, enabling precise and non-invasive lesion targeting, and enhance drug delivery. However, pharmacokinetic studies are required to quantitatively assess improvements in drug uptake. Most studies are phase I clinical trials, and long-term follow-up investigating patient outcomes is essential to evaluate the clinical benefit of this treatment approach. Further studies involving diverse populations and pathologies will be beneficial.

Citing Articles

Nanotherapy of Glioblastoma-Where Hope Grows.

Grzegorzewski J, Michalak M, Woloszczuk M, Bulicz M, Majchrzak-Celinska A Int J Mol Sci. 2025; 26(5).

PMID: 40076445 PMC: 11898975. DOI: 10.3390/ijms26051814.

References

Kobus T, Vykhodtseva N, Pilatou M, Zhang Y, McDannold N . Safety Validation of Repeated Blood-Brain Barrier Disruption Using Focused Ultrasound. Ultrasound Med Biol. 2015; 42(2):481-92. PMC: 4816071. DOI: 10.1016/j.ultrasmedbio.2015.10.009. View

Martinez P, Nault G, Steiner J, Wempe M, Pierce A, Brunt B . MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model. Neurooncol Adv. 2023; 5(1):vdad111. PMC: 10547466. DOI: 10.1093/noajnl/vdad111. View

Linville R, DeStefano J, Sklar M, Chu C, Walczak P, Searson P . Modeling hyperosmotic blood-brain barrier opening within human tissue-engineered in vitro brain microvessels. J Cereb Blood Flow Metab. 2019; 40(7):1517-1532. PMC: 7308510. DOI: 10.1177/0271678X19867980. View

Stine C, Munson J . Convection-Enhanced Delivery: Connection to and Impact of Interstitial Fluid Flow. Front Oncol. 2019; 9:966. PMC: 6783516. DOI: 10.3389/fonc.2019.00966. View

Aryal M, Vykhodtseva N, Zhang Y, Park J, McDannold N . Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release. 2013; 169(1-2):103-11. PMC: 3952428. DOI: 10.1016/j.jconrel.2013.04.007. View

Tsutsui J, Xie F, Porter R . The use of microbubbles to target drug delivery. Cardiovasc Ultrasound. 2004; 2:23. PMC: 538251. DOI: 10.1186/1476-7120-2-23. View

Blackmore D, Turpin F, Mohamed A, Zong F, Pandit R, Pelekanos M . Multimodal analysis of aged wild-type mice exposed to repeated scanning ultrasound treatments demonstrates long-term safety. Theranostics. 2019; 8(22):6233-6247. PMC: 6299703. DOI: 10.7150/thno.27941. View

Chang S, Kuhn J, Robins H, Schold Jr S, Spence A, Berger M . A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer. 2001; 91(2):417-22. DOI: 10.1002/1097-0142(20010115)91:2<417::aid-cncr1016>3.0.co;2-9. View

OReilly M, Hynynen K . Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012; 263(1):96-106. PMC: 3309801. DOI: 10.1148/radiol.11111417. View

10.

OReilly M, Jones R, Barrett E, Schwab A, Head E, Hynynen K . Investigation of the Safety of Focused Ultrasound-Induced Blood-Brain Barrier Opening in a Natural Canine Model of Aging. Theranostics. 2017; 7(14):3573-3584. PMC: 5596444. DOI: 10.7150/thno.20621. View

11.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

12.

Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Front Oncol. 2020; 10:1663. PMC: 7511634. DOI: 10.3389/fonc.2020.01663. View

13.

Abbott N . Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005; 25(1):5-23. PMC: 11529509. DOI: 10.1007/s10571-004-1374-y. View

14.

Zhang D, Dmello C, Chen L, Arrieta V, Gonzalez-Buendia E, Kane J . Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clin Cancer Res. 2019; 26(2):477-486. PMC: 7050644. DOI: 10.1158/1078-0432.CCR-19-2182. View

15.

Kong C, Chang W . Preclinical Research on Focused Ultrasound-Mediated Blood-Brain Barrier Opening for Neurological Disorders: A Review. Neurol Int. 2023; 15(1):285-300. PMC: 9944161. DOI: 10.3390/neurolint15010018. View

16.

Sonabend A, Gould A, Amidei C, Ward R, Schmidt K, Zhang D . Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023; 24(5):509-522. PMC: 10256454. DOI: 10.1016/S1470-2045(23)00112-2. View

17.

van den Bent M, Eoli M, Sepulveda J, Smits M, Walenkamp A, Frenel J . INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2019; 22(5):684-693. PMC: 7229258. DOI: 10.1093/neuonc/noz222. View

18.

Cho H, Lee H, Han M, Choi J, Ahn S, Lee T . Localized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain. Sci Rep. 2016; 6:31201. PMC: 4980618. DOI: 10.1038/srep31201. View

19.

Chai W, Chu P, Tsai M, Lin Y, Wang J, Wei K . Magnetic-resonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood-brain barrier opening and brain drug delivery. J Control Release. 2014; 192:1-9. DOI: 10.1016/j.jconrel.2014.06.023. View

20.

Park S, Kim M, Jung H, Chang W, Choi H, Rachmilevitch I . Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J Neurosurg. 2020; 134(2):475-483. DOI: 10.3171/2019.10.JNS192206. View